STOCK TITAN

[SCHEDULE 13G/A] FibroGen, Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 336,000 shares of FibroGen, Inc. common stock, representing 8.31% of the outstanding class based on the issuer's reported share count in its most recent 10-Q. Armistice Capital acts as investment manager to the Master Fund, the direct holder of the shares, and exercises shared voting and dispositive power over the reported securities. Mr. Boyd, as managing member of Armistice Capital, is similarly reported to have shared voting and dispositive power. The Master Fund disclaims direct beneficial ownership due to the investment management arrangement.

Armistice Capital, LLC e Steven Boyd dichiarano la titolarità effettiva di 336.000 azioni ordinarie di FibroGen, Inc., pari all'8,31% della classe in circolazione secondo il numero di azioni riportato dall'emittente nell'ultimo 10-Q. Armistice Capital agisce come gestore degli investimenti del Master Fund, detentore diretto delle azioni, e esercita congiuntamente il diritto di voto e il potere dispositvo sui titoli segnalati. Il sig. Boyd, in qualità di membro dirigente di Armistice Capital, è indicato allo stesso modo come titolare di diritti di voto e di disposizione condivisi. Il Master Fund rinuncia alla titolarità diretta effettiva a causa dell'accordo di gestione degli investimenti.

Armistice Capital, LLC y Steven Boyd informan la titularidad efectiva de 336.000 acciones ordinarias de FibroGen, Inc., que representan el 8,31% de la clase en circulación según el recuento de acciones informado por el emisor en su último 10-Q. Armistice Capital actúa como gestor de inversiones del Master Fund, titular directo de las acciones, y ejerce de forma conjunta el poder de voto y el poder dispositivo sobre los valores informados. El Sr. Boyd, como miembro gerente de Armistice Capital, se indica de la misma forma que tiene poderes compartidos de voto y disposición. El Master Fund renuncia a la titularidad beneficiaria directa debido al acuerdo de gestión de inversiones.

Armistice Capital, LLC와 Steven Boyd는 발행사의 최신 10-Q에 보고된 주식수 기준으로 FibroGen, Inc. 보통주 336,000주(발행 주식의 8.31%)에 대한 수익적 소유를 신고합니다. Armistice Capital은 해당 주식을 직접 보유한 실체인 마스터 펀드의 투자운용사로서 보고된 증권에 대해 공동으로 의결권 및 처분권을 행사합니다. Boyd 씨는 Armistice Capital의 관리 구성원으로서 동일하게 공동 의결권 및 처분권을 보유한 것으로 보고됩니다. 마스터 펀드는 투자운용 계약으로 인해 직접적인 수익적 소유를 부인합니다.

Armistice Capital, LLC et Steven Boyd déclarent la propriété bénéficiaire de 336 000 actions ordinaires de FibroGen, Inc., représentant 8,31 % de la catégorie en circulation sur la base du nombre d'actions déclaré par l'émetteur dans son dernier 10‑Q. Armistice Capital agit en tant que gestionnaire d'investissement du Master Fund, détenteur direct des actions, et exerce conjointement le droit de vote et le pouvoir de disposition sur les titres déclarés. M. Boyd, en tant que membre dirigeant d'Armistice Capital, est de même indiqué comme exerçant des pouvoirs partagés de vote et de disposition. Le Master Fund décline toute propriété bénéficiaire directe en raison de l'accord de gestion des investissements.

Armistice Capital, LLC und Steven Boyd melden wirtschaftliches Eigentum an 336.000 Aktien der Stammaktien von FibroGen, Inc., was 8,31% der ausstehenden Aktienklasse entspricht, basierend auf der vom Emittenten im jüngsten 10‑Q gemeldeten Aktienanzahl. Armistice Capital fungiert als Investmentmanager des Master Fund, des unmittelbaren Inhabers der Aktien, und übt gemeinschaftlich Stimmbefugnis und Verfügungsgewalt über die gemeldeten Wertpapiere aus. Herr Boyd ist als geschäftsführendes Mitglied von Armistice Capital ebenfalls als gemeinsamer Inhaber von Stimm- und Verfügungsrechten angegeben. Der Master Fund lehnt aufgrund der Anlageverwaltungsvereinbarung ein unmittelbares wirtschaftliches Eigentum ab.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: A single investment manager reports an 8.31% stake, signaling a meaningful equity position disclosed under Schedule 13G/A.

Armistice Capital's filing shows it manages a material minority stake in FibroGen through its Master Fund and reports shared voting and dispositive power over 336,000 shares. This is a passive ownership disclosure consistent with Schedule 13G/A practice where the filer states holdings are in the ordinary course of business and not intended to influence control. The reported percentage is calculated using the issuer's share count from its recent 10-Q and therefore reflects a non-trivial ownership level that could be relevant to shareholder composition analyses.

TL;DR: The filing documents joint reporting by manager and individual and clarifies governance/control relationships.

The statement delineates Armistice Capital's role as investment manager and Mr. Boyd's position as managing member, with both acknowledging shared voting and dispositive authority for the reported shares. The Master Fund's disclaimer of direct beneficial ownership due to the investment management agreement is explicitly stated, reducing ambiguity about who holds legal title versus who directs voting and disposition. The joint filing statement confirms responsibility-sharing for amendments and accuracy of reported information.

Armistice Capital, LLC e Steven Boyd dichiarano la titolarità effettiva di 336.000 azioni ordinarie di FibroGen, Inc., pari all'8,31% della classe in circolazione secondo il numero di azioni riportato dall'emittente nell'ultimo 10-Q. Armistice Capital agisce come gestore degli investimenti del Master Fund, detentore diretto delle azioni, e esercita congiuntamente il diritto di voto e il potere dispositvo sui titoli segnalati. Il sig. Boyd, in qualità di membro dirigente di Armistice Capital, è indicato allo stesso modo come titolare di diritti di voto e di disposizione condivisi. Il Master Fund rinuncia alla titolarità diretta effettiva a causa dell'accordo di gestione degli investimenti.

Armistice Capital, LLC y Steven Boyd informan la titularidad efectiva de 336.000 acciones ordinarias de FibroGen, Inc., que representan el 8,31% de la clase en circulación según el recuento de acciones informado por el emisor en su último 10-Q. Armistice Capital actúa como gestor de inversiones del Master Fund, titular directo de las acciones, y ejerce de forma conjunta el poder de voto y el poder dispositivo sobre los valores informados. El Sr. Boyd, como miembro gerente de Armistice Capital, se indica de la misma forma que tiene poderes compartidos de voto y disposición. El Master Fund renuncia a la titularidad beneficiaria directa debido al acuerdo de gestión de inversiones.

Armistice Capital, LLC와 Steven Boyd는 발행사의 최신 10-Q에 보고된 주식수 기준으로 FibroGen, Inc. 보통주 336,000주(발행 주식의 8.31%)에 대한 수익적 소유를 신고합니다. Armistice Capital은 해당 주식을 직접 보유한 실체인 마스터 펀드의 투자운용사로서 보고된 증권에 대해 공동으로 의결권 및 처분권을 행사합니다. Boyd 씨는 Armistice Capital의 관리 구성원으로서 동일하게 공동 의결권 및 처분권을 보유한 것으로 보고됩니다. 마스터 펀드는 투자운용 계약으로 인해 직접적인 수익적 소유를 부인합니다.

Armistice Capital, LLC et Steven Boyd déclarent la propriété bénéficiaire de 336 000 actions ordinaires de FibroGen, Inc., représentant 8,31 % de la catégorie en circulation sur la base du nombre d'actions déclaré par l'émetteur dans son dernier 10‑Q. Armistice Capital agit en tant que gestionnaire d'investissement du Master Fund, détenteur direct des actions, et exerce conjointement le droit de vote et le pouvoir de disposition sur les titres déclarés. M. Boyd, en tant que membre dirigeant d'Armistice Capital, est de même indiqué comme exerçant des pouvoirs partagés de vote et de disposition. Le Master Fund décline toute propriété bénéficiaire directe en raison de l'accord de gestion des investissements.

Armistice Capital, LLC und Steven Boyd melden wirtschaftliches Eigentum an 336.000 Aktien der Stammaktien von FibroGen, Inc., was 8,31% der ausstehenden Aktienklasse entspricht, basierend auf der vom Emittenten im jüngsten 10‑Q gemeldeten Aktienanzahl. Armistice Capital fungiert als Investmentmanager des Master Fund, des unmittelbaren Inhabers der Aktien, und übt gemeinschaftlich Stimmbefugnis und Verfügungsgewalt über die gemeldeten Wertpapiere aus. Herr Boyd ist als geschäftsführendes Mitglied von Armistice Capital ebenfalls als gemeinsamer Inhaber von Stimm- und Verfügungsrechten angegeben. Der Master Fund lehnt aufgrund der Anlageverwaltungsvereinbarung ein unmittelbares wirtschaftliches Eigentum ab.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:08/15/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:08/15/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 15, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

Fibrogen Inc

NASDAQ:FGEN

FGEN Rankings

FGEN Latest News

FGEN Latest SEC Filings

FGEN Stock Data

39.93M
3.98M
1.58%
31.02%
3.7%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO